Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Clears Takeda Uloric For Gout Indication

This article was originally published in PharmAsia News

Executive Summary

Despite concerns about cardiac safety, U.S. FDA approved Takeda's Uloric (febuxostat) for the chronic management of hyperuricemia in patients with gout Feb. 13. The approval marks the first new FDA-approved treatment for gout in more than 40 years

You may also be interested in...



Bristol-Myers Squibb Inks Licensing Deal With Nissan Chemical And Teijin Pharma For Atrial Fibrillation Compound

Bristol-Myers Squibb signed a licensing agreement with Tokyo-based Nissan Chemical Industries and Teijin Pharma March 4, which gives BMS worldwide rights, excluding Japan, to develop and market atrial fibrillation compound NTC-801, currently in Phase I in Japan

Bristol-Myers Squibb Inks Licensing Deal With Nissan Chemical And Teijin Pharma For Atrial Fibrillation Compound

Bristol-Myers Squibb signed a licensing agreement with Tokyo-based Nissan Chemical Industries and Teijin Pharma March 4, which gives BMS worldwide rights, excluding Japan, to develop and market atrial fibrillation compound NTC-801, currently in Phase I in Japan

Takeda Readying To Launch PPI Kapidex Within A Month

TOKYO - Takeda expects to launch within a month its Kapidex (dexlansoprazole) delayed- release capsules for the treatment of gastroesophageal reflux disease, the same proton pump inhibitor class of drugs as its Prevacid, which is scheduled to lose patent protection this year, according to the company's third-quarter earnings call Feb. 3

Related Content

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel